Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Organisation › Details

Spero Therapeutics Inc.

Spero Therapeutics is a global multi-asset clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to developing a novel and highly differentiated pipeline of antibacterials focused on unmet needs of patients with drug resistant bacterial infections. Spero Therapeutics is advancing two lead programs in parallel, SPR741 and SPR994. SPR741, also called Potentiator, is a platform approach to combination therapy to treat serious and life-threatening multi-drug resistant gram negative infections, such as Enterobacteriaceae and Acinetobacter baumanii, including carbapenem resistant strains. SPR741 increases the spectrum and potency of more than two dozen classes of gram positive antibiotics to include activity against multidrug resistant gram negative infections when used in combination. SPR994 is a novel oral agent that has demonstrated potent in–vitro activity against a wide variety of gram-negative bacteria, including extended spectrum beta lactamases (ESBLs), and gram-positive bacteria. Spero Therapeutics also has a robust preclinical pipeline including SPR720, which is a preclinical oral asset for nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic fatal infection. In addition, Spero Therapeutics has a variety of other discovery antimicrobials focused on drug-resistant infections. *

 

Period Start 2019-06-13 renamed before
  Predecessor Spero Therapeutics LLC
Product Industry antibiotic
Persons Person Mahadevia, Ankit (Atlas Venture 201306 Venture Partner)
  Person 2 Sendek, Joel (Spero Therapeutics 201705– CFO before Forward Pharma A/S + Stifel Financial Corp + Lazard +Progenics)
     
Region Region Cambridge, MA
  Country United States (USA)
  City n. a. 
    Address record changed: 2019-06-14
     
Basic data Employees n. a.
     
    * Document for �About Section�: Spero Therapeutics, LLC. (3/8/17). "Press Release: Spero Therapeutics Secures $51.7 Million in Oversubscribed Series C Financing". Cambridge, MA.
     
   
Record changed: 2019-06-15

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Spero Therapeutics Inc.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px




» top